Lilly’s Van Naarden: Nothing is off the table for dealmaking

Summary

Jake Van Naarden, Lilly's President of Oncology and Head of Business Development, discusses the company's oncology pipeline and dealmaking strategy at ASCO. He highlights eight upcoming cancer medicine launches that he believes are underappreciated, and explains how Lilly's GLP-1 windfall is being redeployed into early and later-stage deals across therapeutic areas including infectious disease.

• Lilly's oncology business is a major growth driver beyond GLP-1s.
• Eight new cancer medicines or label expansions are in the pipeline with promising data.
• Lilly is executing a two-pronged deal strategy: many early-stage low-cost deals and fewer later-stage derisked acquisitions.
• No arbitrary limits on deal size; focus on compelling science and patient impact.
• Infectious disease and vaccines have become a new focus area for Lilly.
• The company is using its financial strength from GLP-1s to redeploy capital across disease areas.